What is the cervical cancer screening schedule per USPSTF?

Prepare for the USPSTF Guidelines Test with comprehensive flashcards and multiple choice questions, each question includes hints and explanations. Get ready for your exam with confidence!

Multiple Choice

What is the cervical cancer screening schedule per USPSTF?

Explanation:
The main idea is that the screening plan for cervical cancer is age- and test-dependent, with options that balance accuracy and practicality. For ages 21–29, the recommended approach is cytology (a Pap test) every 3 years. Starting at age 30, you have two valid paths: either cytology alone every 3 years or co-testing with both cytology and an HPV test every 5 years. If a person has had adequate prior screening and no high-grade abnormalities, screening can stop at age 65. This aligns with the best answer because it captures both the age-specific intervals and the two acceptable testing strategies after age 30, plus the stop-at-65 criterion with adequate prior screening. The other options misstate the schedule by favoring annual testing, insisting on stopping at 65 without considering prior screening history, or listing only cytology every 3 years for 30–65 without acknowledging that HPV co-testing every 5 years is also an acceptable alternative.

The main idea is that the screening plan for cervical cancer is age- and test-dependent, with options that balance accuracy and practicality. For ages 21–29, the recommended approach is cytology (a Pap test) every 3 years. Starting at age 30, you have two valid paths: either cytology alone every 3 years or co-testing with both cytology and an HPV test every 5 years. If a person has had adequate prior screening and no high-grade abnormalities, screening can stop at age 65.

This aligns with the best answer because it captures both the age-specific intervals and the two acceptable testing strategies after age 30, plus the stop-at-65 criterion with adequate prior screening. The other options misstate the schedule by favoring annual testing, insisting on stopping at 65 without considering prior screening history, or listing only cytology every 3 years for 30–65 without acknowledging that HPV co-testing every 5 years is also an acceptable alternative.

Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy